YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Agios Pharmaceuticals, Inc. CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare dise…
Shares of Agios Pharmaceuticals AGIO have declined 29% over the past three months despite strong growth in mitapivat sales in the second quarter of 2026. The decline largely reflects setbacks to tebapivat, a key pipeline candidate, which h…
Agios Pharmaceuticals AGIO is entering an important phase of its growth story as its lead therapy, mitapivat, expands across multiple blood disorders. The drug is marketed as Pyrukynd for pyruvate kinase (PK) deficiency and as Aqvesme for…
A month has gone by since the last earnings report for Revolution Medicines, Inc. (RVMD). Shares have added about 6.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings r…
Agios Pharmaceuticals AGIO reported a loss of $1.69 per share for the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $1.86. In the year-ago quarter, the company had incurred a loss of $1.93 per share. Total…
This article first appeared on GuruFocus. Total Mitapivat Net Revenue: $44.7 million for Q2 2026, including $40.9 million in the US and $3.8 million outside the US. AQVESME Prescriptions: 442 cumulative prescriptions from REMS-certified ph…
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.69 per share versus the Zacks Consensus Estimate of a loss of $1.86. This compares to a loss of $1.93 per share a year ago. These figures are adjusted for non-recurring item…
Agios Pharmaceuticals, Inc. Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025 Strong U.S. commercial launch of AQVESM…
Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025 Strong U.S. commercial launch of AQVESME in thalassemia, with 442 c…
In July 2026, Agios Pharmaceuticals reported topline Phase 2 results for tebapivat in sickle cell disease, showing hemoglobin and hemolysis improvements but insufficient differentiation versus placebo, and consequently decided to discontin…
For Immediate Release Chicago, IL – July 28, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial mar…
The second-quarter 2026 reporting cycle for the Medical sector is picking up pace. The sector primarily comprises pharma/biotech and medical device companies. The earnings season for the Medical sector kicked off earlier this month when ph…
Neurocrine Biosciences NBIX is scheduled to report second-quarter 2026 results on July 30, after market close. We expect investors to focus on the sales performance of NBIX's marketed products and other pipeline updates when the company re…
The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the…
Wall Street expects a year-over-year increase in earnings on higher revenues when Agios Pharmaceuticals (AGIO) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's…
Agios Pharmaceuticals AGIO announced that it has discontinued the development of its investigational drug, tebapivat, for the treatment of patients with sickle cell disease (SCD) after phase II study data failed to demonstrate sufficient c…
The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +0.89%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.74%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.93%. September E-mini S&P futures (ESU26) rose +0.81%, and Sep…
The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +0.89%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.74%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.93%. September E-mini S&P futures (ESU26) rose +0.81%, and Sep…
The S&P 500 Index ($SPX) (SPY) today is up +0.64%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.47%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.58%. September E-mini S&P futures (ESU26) are up +0.62%, and September E-mini N…
The S&P 500 Index ($SPX) (SPY) today is up +0.38%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.17%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.26%. September E-mini S&P futures (ESU26) are up +0.35%, and September E-mini N…
The S&P 500 Index ($SPX) (SPY) today is up +0.64%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.47%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.58%. September E-mini S&P futures (ESU26) are up +0.62%, and September E-mini N…
The S&P 500 Index ($SPX) (SPY) today is up +0.38%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.17%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.26%. September E-mini S&P futures (ESU26) are up +0.35%, and September E-mini N…
Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled. Continue Reading
Agios Pharmaceuticals, Inc. Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in sickle cell…
Key Points Agios stock surged after FDA granted priority review for mitapivat in sickle cell disease. Mitapivat showed mixed Phase 3 results, and competition is coming from Novo Nordisk.10 stocks we like better than Agios Pharmaceuticals ›…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Agios Pharmaceuticals (AGIO) is back in focus after the US Food and Drug Administration accepted it…
In early July 2026, Agios Pharmaceuticals announced that the U.S. FDA had accepted its supplemental New Drug Application for mitapivat in sickle cell disease under the accelerated approval pathway and granted it Priority Review, setting a…
Agios Pharmaceuticals AGIO announced that the FDA has accepted its supplemental new drug application (sNDA) seeking approval for its lead product, mitapivat, an oral pyruvate kinase (PK) activator, for the treatment of sickle cell disease…
Agios Pharmaceuticals (AGIO) shares soared 17.7% in the last trading session to close at $44.01. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 36.3% gain over…
Key Points The company took a major step toward an accelerated approval of mitapivat in sickle cell disease today. Agios needs to complete a confirmatory trial before a full traditional approval can be granted. 10 stocks we like better tha…
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) were higher by more than 14% as of 11 a.m this morning. The move comes after a very positive development from the Food and Drug Administration (FDA) on its key drug, mitapivat. Agios and mitap…
Agios stock skyrocketed closer to a profit-taking zone Tuesday after the FDA assigned its sickle cell drug a speedy review. Continue Reading
Moderna (MRNA), TG Therapeutics (TGTX), and Agios Pharmaceuticals (AGIO) will see increased scrutiny PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
(RTTNews) - Agios Pharmaceuticals Inc. (AGIO), a commercial-stage biopharmaceutical company, on Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted under a priority review the supplemental new drug application (…
(RTTNews) - Agios Pharmaceuticals, Inc. (AGIO) on Tuesday said the U.S. Food and Drug Administration (FDA) has granted Priority Review to its supplemental New Drug Application (sNDA) for mitapivat as a treatment for sickle cell disease. Th…
Agios Pharmaceuticals, Inc. FDA's PDUFA goal date is November 1, 2026 If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agio…